Silexion restates FY2025 financials for 1-for-10 reverse split; auditor flags going concern

Silexion Therapeutics Corp

FY2025 net loss $11.9M vs $16.5M in 2024; operating loss $11.6M vs $12.6M.
Cash and equivalents $5.99M at Dec 31, 2025, up from $1.19M; total assets $7.2M.
Auditor expresses substantial doubt about ability to continue as going concern due to recurring losses.
1-for-10 reverse split effective May 28, 2026; all share and per-share data retroactively adjusted.
R&D spend rose to $7.1M from $5.8M; G&A fell to $4.5M from $6.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.